CoreCap Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

CoreCap Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.6K	Sell	800 -1,385	-63%	-$22.1K	﹤0.01%	1960
2026 Q1	$32.4K	Sell	2,185 -22,584	-91%	-$330K	﹤0.01%	1488
2025 Q4	$395K	Buy	24,769 +23,969	+2,996%	+$340K	0.01%	573
2025 Q3	$8.84K	Hold	800	–	–	﹤0.01%	1993
2025 Q2	$6.78K	Hold	800	–	–	﹤0.01%	2027
2025 Q1	$6.43K	Hold	800	–	–	﹤0.01%	2004
2024 Q4	$7.18K	Hold	800	–	–	﹤0.01%	1889
2024 Q3	$5.86K	Hold	800	–	–	﹤0.01%	1935
2024 Q2	$4.57K	Hold	800	–	–	﹤0.01%	1187
2024 Q1	$4.01K	Buy	+800	New	+$5.43K	﹤0.01%	1965
2022 Q4	$3.46K	Buy	+800	New	+$4.64K	﹤0.01%	1836
2022 Q3	–	Sell	-800	Closed	-$8K	–	646
2022 Q2	$8K	Buy	+800	New	+$8.94K	﹤0.01%	1527
2022 Q1	–	Sell	-800	Closed	-$18K	–	655
2021 Q4	$18K	Buy	+800	New	+$19K	﹤0.01%	1354

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CoreCap Advisors's AUPH Position: Q2 2026 in Review

CoreCap Advisors reduced its Aurinia Pharmaceuticals (AUPH) stake by 63% in Q2 2026, selling an estimated $22.1K and leaving 800 shares worth $13.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1960.

CoreCap Advisors first reported a position in AUPH in Q4 2021 and has held it in 13 quarters since. The position peaked at $395K in Q4 2025. 281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

CoreCap Advisors held 800 shares of Aurinia Pharmaceuticals worth $13.6K as of Q2 2026.
CoreCap Advisors sold 1,385 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $22.1K.
Aurinia Pharmaceuticals made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #1960 holding.
CoreCap Advisors first reported a position in Aurinia Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
CoreCap Advisors's Aurinia Pharmaceuticals position peaked at $395K in Q4 2025.
281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.